WASHINGTON, D.C. — Ten prescription drugs will cost less for Medicare beneficiaries starting in 2026.
A provision of the Inflation Reduction Act secured by U.S. Sen. Sherrod Brown allows the U.S. Department of Health and Human Services secretary to negotiate prices directly with drug manufacturers.
Brown’s office estimates the price reductions will save Medicare beneficiaries $1.5 billion in out-of-pocket costs the first year alone.
The changes cover popular blood thinners Eliquis and Xarelto; diabetes medications Jardiance, Januvia, Farxiga and Fiasp; heart failure medication Entresto; arthritis and psoriasis medications Enbrel and Stelara; and blood cancer medication Imbruvica.
An estimated 381,000 Ohioans enrolled in Medicare take at least one of these medications, according to Brown’s office.
The new prices take effect Jan. 1, 2026.
“After years of fighting Big Pharma and their lobbyists, we are bringing down drug prices for Ohioans,” Brown said in a news release announcing the changes. “Soon many Ohioans on Medicare will be able to take advantage of negotiated lower prices for 10 popular prescriptions.
“I will continue to take on the drug companies and work to bring down drug costs for all Ohioans.”
LIST PRICE CHANGES FOR MEDICARE PART D
Januvia: $113 for 30-day supply, a 79% discount from previous cost of $527.
Fiasp: $119 for 30-day supply, 76% discount from previous cost of $495.
Farxiga: $178.50 for 30-day supply, a 68% discount from previous cost of $556.
Enbrel: $2,355 for 30-day supply, a 67% discount from previous cost of $7,106.
Jardiance: $197 for 30-day supply, a 66% discount from previous cost of $573.
Stelara: $4,695 for 30-day supply, a 66% discount from previous cost of $13,836.
Xarelto: $197 for 30-day supply, a 62% discount from previous cost of $517.
Eliquis: $231 for 30-day supply, a 56% discount from previous cost of $521.
Entresto: $295 for 30-day supply, a 53% discount from previous cost of $628.
Imbruvica: $9,319 for 30-day supply, a 38% discount from previous cost of $14,934.
